APA

Franke N. E., Niewerth D., Assaraf Y. G., van Meerloo J., Vojtekova K., van Zantwijk C. H., Zweegman S., Chan E. T., Kirk C. J., Geerke D. P., Schimmer A. D., Kaspers G. J. L., Jansen G. & Cloos J. (20120604). Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. : Leukemia.

Chicago

Franke N E, Niewerth D, Assaraf Y G, van Meerloo J, Vojtekova K, van Zantwijk C H, Zweegman S, Chan E T, Kirk C J, Geerke D P, Schimmer A D, Kaspers G J L, Jansen G and Cloos J. 20120604. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. : Leukemia.

Harvard

Franke N. E., Niewerth D., Assaraf Y. G., van Meerloo J., Vojtekova K., van Zantwijk C. H., Zweegman S., Chan E. T., Kirk C. J., Geerke D. P., Schimmer A. D., Kaspers G. J. L., Jansen G. and Cloos J. (20120604). Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. : Leukemia.

MLA

Franke N E, Niewerth D, Assaraf Y G, van Meerloo J, Vojtekova K, van Zantwijk C H, Zweegman S, Chan E T, Kirk C J, Geerke D P, Schimmer A D, Kaspers G J L, Jansen G and Cloos J. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. : Leukemia. 20120604.